🇬🇧·4h agoRegulatory
UPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31
Publisher
M
MHRA UK
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- MHRA UK
- Region
- UK
- Scope
- Regulatory
- Published
- July 7, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on gov.uk
Leave the platform to read the original full article on the publisher site.
Source: MHRA UK
Scope: Regulatory
Related coverage
More related coverage
ABPI UK/4h ago
Package deals in the pharmaceutical industry and Disclosure UK data
ABPI UK/4h ago
Disclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to grow
ABPI UK/4h ago
Updates to the NHS Commercial Framework must deliver more flexibility to support timely access to medicines
ABPI UK/4h ago